A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Non-Small Cell Lung Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 587 (final count)
- Started
- Jul 2, 2019
- Main results expected
- Apr 3, 2023
- Fully finished
- Sep 30, 2027
- Results posted
- Aug 6, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
Adverse Events Graded by Common Terminology Criteria for Adverse Event v5 (Safety Run-In Treatment Arms Only)
Measured over: From first dose date to 28 days following last dose, up to 45 months
Progression-free Survival (PFS) (Randomized Component)
Measured over: Up to approximately 33 months after the first patient is randomized (maximum follow up of 33.3 months)
Sensitivity Analysis for Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Randomized Component)
Measured over: Up to approximately 33 months after the first patient is randomized (maximum follow up of 33.2 months).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04035486 · record last updated 2026-09-03 · checked 2026-11-09 15:47 UTC